California State Teachers Retirement System boosted its holdings in shares of Wave Life Sciences Ltd (NASDAQ:WVE) by 43.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,009 shares of the company’s stock after buying an additional 6,400 shares during the quarter. California State Teachers Retirement System owned approximately 0.08% of Wave Life Sciences worth $391,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nationwide Fund Advisors increased its position in Wave Life Sciences by 58.1% during the second quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock worth $125,000 after buying an additional 2,470 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Wave Life Sciences by 71.0% during the second quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after buying an additional 3,912 shares during the last quarter. Strs Ohio grew its position in shares of Wave Life Sciences by 6.3% in the second quarter. Strs Ohio now owns 11,900 shares of the company’s stock valued at $221,000 after purchasing an additional 700 shares during the last quarter. Rhumbline Advisers grew its position in shares of Wave Life Sciences by 62.3% in the second quarter. Rhumbline Advisers now owns 12,502 shares of the company’s stock valued at $233,000 after purchasing an additional 4,800 shares during the last quarter. Finally, New York State Common Retirement Fund grew its position in shares of Wave Life Sciences by 64.9% in the second quarter. New York State Common Retirement Fund now owns 12,700 shares of the company’s stock valued at $236,000 after purchasing an additional 4,999 shares during the last quarter. 73.74% of the stock is currently owned by hedge funds and other institutional investors.

Wave Life Sciences Ltd (NASDAQ:WVE) opened at $36.80 on Monday. Wave Life Sciences Ltd has a 12-month low of $15.15 and a 12-month high of $39.70. The company has a current ratio of 11.50, a quick ratio of 11.50 and a debt-to-equity ratio of 0.01.

Wave Life Sciences (NASDAQ:WVE) last posted its earnings results on Thursday, November 9th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.03. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.77 million. Wave Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. equities analysts predict that Wave Life Sciences Ltd will post -3.76 EPS for the current year.

WVE has been the topic of several research reports. Zacks Investment Research raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 12th. BidaskClub raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Leerink Swann reaffirmed an “outperform” rating and issued a $53.00 target price (up previously from $42.00) on shares of Wave Life Sciences in a research report on Wednesday, November 15th. Finally, Mizuho set a $34.00 target price on Wave Life Sciences and gave the company a “buy” rating in a research report on Friday, August 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Wave Life Sciences currently has a consensus rating of “Buy” and an average target price of $41.60.

In related news, insider Chandra Vargeese sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $35.00, for a total value of $52,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Masaharu Tanaka sold 20,747 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $24.21, for a total value of $502,284.87. The disclosure for this sale can be found here. Insiders own 53.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/wave-life-sciences-ltd-wve-holdings-boosted-by-california-state-teachers-retirement-system/1757043.html.

Wave Life Sciences Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.